The US Food and Drug Administration has taken steps to make it easier for patients with serious or immediately life-threatening illnesses to be treated under the agency's expanded access, or compassionate use, program1-3.
The program allows patients to be treated with experimental drugs in cases where there are no comparable alternatives.